Eisai Showcases Advancements in Endometrial Cancer Treatments at IGCS 2025

Eisai Inc. has recently made headlines by presenting significant advancements in the treatment of advanced endometrial cancer at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, held in Cape Town, South Africa, from November 5 to 7, 2025. This year's conference highlighted key findings from the long-term follow-up of the Phase 3 study 309/KEYNOTE-775, which evaluated the combined efficacy of lenvatinib (LENVIMA®) and pembrolizumab (KEYTRUDA®) for patients subjected to prior treatments for endometrial carcinoma.

The data presented focus on five-year survival outcomes in patients who received these treatments following at least one previous platinum-based regimen. The highlight of this presentation, which Dr. Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai, emphasized, represents the longest available data on the combination of a TKI (tyrosine kinase inhibitor) and checkpoint inhibitor in this particular setting. The findings indicate durable antitumor activity, without the emergence of new safety signals among patients battling advanced endometrial cancer.

In addition to Study 309/KEYNOTE-775, Eisai revealed an analysis centered on the efficacy of lenvatinib combined with pembrolizumab versus chemotherapy. This analysis specifically scrutinizes outcomes in patients whose only previous therapy consisted of (neo)adjuvant chemotherapy. The results underscore a crucial understanding of treatment pathways for patients whose conditions deteriorated after prior systemic therapies.

Moreover, Eisai's presentations at IGCS also encompassed real-world evidence concerning the comparative effectiveness of the lenvatinib and pembrolizumab regimen versus traditional single-agent chemotherapy in American patients with recurrent or advanced endometrial carcinoma. This study particularly targets cases deemed mismatch repair proficient (pMMR) or those without microsatellite instability-high (MSI-H).

Eisai's commitment to advancing cancer treatment extends beyond the conference presentations. Lenvatinib is already FDA-approved in various jurisdictions, including the United States and Europe, for treating numerous forms of advanced cancer, including endometrial carcinoma and renal cell carcinoma. The ongoing collaboration with Merck to co-develop this drug signifies a robust partnership aimed at enhancing treatment outcomes for patients worldwide.

As the medical community continues to gather insights from the data shared at IGCS 2025, the focus remains on providing optimized treatment strategies for recurrent and advanced gynecological cancers. According to Dr. Dutcus, “The findings presented offer substantial insights that not only contribute to our understanding of endometrial cancer treatment but also empower clinicians in making informed decisions for their patients.”

This significant presentation reinforces Eisai's commitment to delivering innovative cancer therapies tailored to the needs of patients with high unmet medical needs. As we await further advancements and research, the discussions at IGCS 2025 pave the way for potential new standards of care in endometrial cancer treatment, promising hope and improved outcomes for patients across the globe.